Is there a circadian variation in plasma concentrations of etoposide given by prolonged continuous infusion?

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 6, 1996, Pages 616-618

  Ando, Yuichi ^a   Minami, Hironobu ^a   Sakai, Shuzo ^b   Shimokata, Kaoru ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

Circadian variation; Etoposide; Low dose infusion; Lung cancer

Indexed keywords

ETOPOSIDE;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CIRCADIAN RHYTHM; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 0030005820     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050438     Document Type: Article

References (13)

1. Bjarnason GA, Hrushesky WJM, Diasio R, Harris J, Marsh R, Huben R, Lokich JJ, Anderson J (1994) Flat versus circadian modified 14 day infusion of FUDR for advanced renal cell cancer (RCC): a phase-III study (abstract). Proc Am Soc Clin Oncol 13: 233
2. Caussanel JP, Lévi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathé G (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046
3. Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PWM, Reznek R, Masud T, Gregory W, Wrigley PFM (1994) A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12: 1427
4. Focan C (1990) Chronotherapy in lung and ovarian cancer (abstract). J Cancer Res Clin Oncol 116 [Suppl 2, part II]: 1073
5. Greco FA (1993) Chronic etoposide administration: overview of clinical experience. Cancer Treat Rev 19 [Suppl c]: 35
6. Hrushesky WJM, Bjarnason GA (1993) Circadian cancer therapy. J Clin Oncol 11: 1403
7. Lévi F, Benavides M, Chevelle C, Le Saunier F, Bailleul F, Misset JL, Regensberg C, Vannetzel JM, Reinberg A, Mathé G (1990) Chemotherapy of advanced ovarian cancer with 4′-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol 8: 705
8. Lévi F, Zidani R, Di Palma M, Faggiuolo R, Garufi C, Chollet P, Focan C, Iacobelli S, Perpoint B, Le Rol A, Itzhaki M, Vannetzel JM, Misset JL (1994) Improved therapeutic index through ambulatory circadian rhythmic delivery (CRD) of high dose 3-drug chemotherapy in a randomized phase III multicenter trial (abstract). Proc Am Soc Clin Oncol 13: 197
9. Minami H, Shimokata K, Saka H, Saito H, Ando Y, Senda K, Nomura F, Sakai S (1993) Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J Clin Oncol 11: 1602
10. O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE (1985) Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med 312: 692
11. Petit E, Gérard M, Lévi F, Thyss A, Bailleul F, Schneider M (1988) Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 48: 1676
12. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F (1991) Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 9: 1480
13. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333